
Genomic Expression is a biotech company specializing in RNA analysis and therapeutics development through its proprietary OneRNA® platform. The platform analyzes all mRNA in patient samples to identify personalized treatment options, particularly in breast and ovarian cancer, enabling repurposing of approved drugs and rapid development of novel RNA therapeutics. It offers a dynamic, AI-powered companion diagnostic that improves patient selection and treatment outcomes, and supports drug development by derisking clinical trials and expanding drug indications. The company has validated its platform clinically, holds key patents in genomics, and collaborates with biotech and pharma to translate RNA code into individualized RNA therapies. Genomic Expression is positioned as a pioneer in RNA-based precision medicine with a scalable, tissue-agnostic platform and a strong management team with industry experience.

Genomic Expression is a biotech company specializing in RNA analysis and therapeutics development through its proprietary OneRNA® platform. The platform analyzes all mRNA in patient samples to identify personalized treatment options, particularly in breast and ovarian cancer, enabling repurposing of approved drugs and rapid development of novel RNA therapeutics. It offers a dynamic, AI-powered companion diagnostic that improves patient selection and treatment outcomes, and supports drug development by derisking clinical trials and expanding drug indications. The company has validated its platform clinically, holds key patents in genomics, and collaborates with biotech and pharma to translate RNA code into individualized RNA therapies. Genomic Expression is positioned as a pioneer in RNA-based precision medicine with a scalable, tissue-agnostic platform and a strong management team with industry experience.
Focus: RNA-sequencing platform (OneRNA) for cancer diagnostics and therapeutics
Stage: Commercial-stage; operates a CLIA lab in Massachusetts
Founders: Gitte Pedersen, Morten Pedersen (additional founder listings include Tanya Kanigan)
Funding: Multiple grants and early rounds; recorded funder EASME; total funding listed as $8,324,488
Precision oncology diagnostics and RNA-based therapeutics development.
2009
Biotechnology
Convertible note announced June 25, 2014 (recorded on funding platform)
Multiple grant rounds and early funding events recorded; grants and accelerator awards noted
“Company materials list investors including Biogen founders, Harvard Business Angels, Investor Circle, Pipeline Angels, and a family office (Centurion Holding); grant funders and accelerators also cited.”